Starpharma Holdings Limited
SPHRY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,712 | $2,427 | $1,731 | $7,197 |
| % Growth | -29.5% | 40.2% | -75.9% | – |
| Cost of Goods Sold | $2,447 | $4,685 | $5,221 | $770 |
| Gross Profit | -$736 | -$2,258 | -$3,490 | $6,427 |
| % Margin | -43% | -93% | -201.6% | 89.3% |
| R&D Expenses | $2,884 | $6,313 | $7,226 | $8,354 |
| G&A Expenses | $725 | $1,581 | $1,493 | $1,040 |
| SG&A Expenses | $1,564 | $3,134 | $3,641 | $3,026 |
| Sales & Mktg Exp. | $839 | $1,553 | $2,148 | $1,987 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,447 | $9,447 | $10,867 | $11,380 |
| Operating Income | -$5,183 | -$11,705 | -$14,357 | $3,610 |
| % Margin | -302.8% | -482.3% | -829.4% | 50.2% |
| Other Income/Exp. Net | $2,884 | $3,157 | $7,226 | -$4,644 |
| Pre-Tax Income | -$2,299 | -$2,696 | -$7,131 | -$1,034 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,299 | -$5,392 | -$7,131 | -$1,034 |
| % Margin | -134.3% | -222.2% | -412% | -14.4% |
| EPS | -0.055 | -0.13 | -0.17 | -0.025 |
| % Growth | 57.7% | 23.5% | -580% | – |
| EPS Diluted | -0.055 | -0.13 | -0.17 | -0.025 |
| Weighted Avg Shares Out | 41,823 | 41,477 | 40,798 | 41,086 |
| Weighted Avg Shares Out Dil | 41,816 | 41,620 | 41,200 | 41,086 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1,278 | $828 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $65 | $138 | $148 | $967 |
| EBITDA | -$2,235 | -$5,254 | -$6,983 | -$2,649 |
| % Margin | -130.6% | -216.5% | -403.4% | -36.8% |